secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117150
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review
--------------------------------------------------------------------------------

- Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.
- IND cleared for VYN201; first patient expected in Phase 1a/b vitiligo trial Nov. 2022 with topline data H1 2023.
- FMX114 Phase 2a missed primary endpoint at week 4 but statistically superior at weeks 1-3; evaluating strategy for moderate-to-severe AD.
- VYN202 oral BETi program progressing with Tay Therapeutics toward lead candidate selection.
- Corporate presentation posted; cash position not separately disclosed in released results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/0001104659-22-117150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/tm2230087d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer